Amgen CD40 Agonistic Multispecific Antibody Constructs for Solid Tumor Treatment
Summary
USPTO granted Patent US12612463B2 to Amgen Inc. on April 28, 2026, covering human agonistic CD40 multispecific antibody constructs engineered to target the CD40 pathway on tumor-associated APCs for solid tumor treatment. The patent lists six inventors: Xin Yu, Jackson Egen, Fernando Garces, Shunsuke Takenaka, AeRyon Kim, and Deepali Sawant, and contains 20 claims under CPC classifications C07K 2317/33 and C07K 16/2878.
“The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.”
About this source
Granted patents in USPTO classification C07K, covering peptides, proteins, antibodies, and related biological molecules. Around 160 grants a month, each with the patent number, title, applicant, inventor names, and full abstract. Unlike published applications (which reveal in-progress research), grants are enforceable rights and signal what a company can now litigate or license. Watch this if you run an antibody or protein biologics program, advise on patent portfolio strategy for biologics companies, scout for licensing opportunities on recently granted claims, or track which research institutions are converting their early peptide work into issued patents.
What changed
USPTO issued Patent US12612463B2 to Amgen Inc. on April 28, 2026, covering mesothelin-targeted CD40 agonistic multispecific antibody constructs for treating solid tumors without systemic CD40 activation. The patent, filed January 19, 2024, with application number 18417708, lists six inventors and contains 20 claims under CPC classifications C07K 2317/33 and C07K 16/2878.
Amgen Inc. now holds exclusive intellectual property rights to this CD40 multispecific antibody construct for solid tumor applications. Competitors developing similar CD40 agonistic antibodies targeting tumor-associated APCs should review the patent claims for potential licensing needs or design-around considerations to avoid infringement.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
Grant US12612463B2 Kind: B2 Apr 28, 2026
Assignee
Amgen Inc.
Inventors
Xin Yu, Jackson Egen, Fernando Garces, Shunsuke Takenaka, AeRyon Kim, Deepali Sawant
Abstract
The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.
CPC Classifications
C07K 2317/33 C07K 16/2878
Filing Date
2024-01-19
Application No.
18417708
Claims
20
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.